National and state treatment need and capacity for opioid agonist medication-assisted treatment

American Journal of Public Health

Volumn 105, Issue 8, 2015, Pages e55-e63

  Jones, Christopher M ^a   Campopiano, Melinda ^b   Baldwin, Grant ^c   McCance Katz, Elinore ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

^c NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

CAPACITY BUILDING; HEALTH SERVICE; HEALTH SURVEY; HUMAN; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANALGESICS, OPIOID; BUPRENORPHINE; CAPACITY BUILDING; HEALTH SERVICES NEEDS AND DEMAND; HEALTH SURVEYS; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 84937009654     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302664     Document Type: Article

References (62)

1. US Department of Health and Human Services. Addressing prescription drug abuse in the United States: current activities and future opportunities. Available at: http://www.cdc.gov/homeandrecreationalsafety/overdose/hhs-rx-abuse.html. Accessed December 8, 2014.
2. Johnson EM, Lanier WA, Merrill RM, et al. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008-2009. J Gen Intern Med. 2013;28(4):522-529.
3. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620.
4. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321.
5. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.
6. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013;132(1-2):95-100.
7. Substance Abuse and Mental Health Services Administration. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. Available at: http://samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.htm. Accessed December 8, 2014.
8. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821-826.
9. Warner M, Hedegaard H, Chen L. Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2012. 2014. Available at: http://www.cdc.gov/nchs/data/hestat/drug-poisoning/drug-poisoning.htm. Accessed December 19, 2014.
10. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55(suppl 1):S3-S9.
11. Zibbell JE, Hart-Malloy R, Barry J, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health. 2014;104(11):2226-2232.
12. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Available at: http://apps.who.int/iris/handle/10665/43948. Accessed December 10, 2014.
13. Kresina TF, Lubran R. Improving public health through access to and utilization of medication assisted treatment. Int J Environ Res Public Health. 2011;8(10):4102-4117.
14. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine consensus panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5(4):254-263.
15. Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc. 2012;104(7-8):342-350.
16. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207-225.
17. Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103(5):917-922.
18. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(suppl 4):S197-S215.
19. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011;30(8):1425-1433.
20. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974-1981.
21. Gryczynski J, Schwartz RP, Salkever DS, Mitchel SG, Jaffe JH. Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat. 2011;41(4):431-439.
22. Andrews CM, Shin HC, Marsh JC, Cao D. Client and program characteristics associated with wait time to substance abuse treatment entry. Am J Drug Alcohol Abuse. 2013;39(1):61-68.
23. Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789.
24. Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359-360.
25. Drug Addiction Treatment Act of 2000, Pub. L. No. 106-310, 114 Stat. 1101. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-106publ310/pdf/PLAW-106publ310.pdf. Accessed November 11, 2014.
26. Greenfield BL, Owens MD, Ley D. Opioid use in Albuquerque, New Mexico: a needs assessment of recent changes and treatment availability. Addict Sci Clin Pract. 2014;9:10.
27. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies - tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066.
28. Sohler NL, Weiss L, Egan JE, et al. Consumer attitudes about opioid addiction treatment: a focus group study in New York City. J Opioid Manag. 2013;9(2):111-119.
29. American Society of Addiction Medicine. State Medicaid coverage and authorization requirements for opioid dependence medications. 2013. Available at: http://www.asam.org/docs/advocacy/Implications-for-Opioid-Addiction-Treatment. Accessed December 10, 2014.
30. Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36(6):584-589.
31. Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV providers. J Gen Intern Med. 2007;22(9):1325-1329.
32. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393-1398.
33. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91-103.
34. Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336-340.
35. Hutchinson E, Catlin M, Andrilla CHA, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128-133.
36. Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244-251.
37. Kunins HV, Sohler NL, Giovanniello A, Thompson D, Cunningham CO. A buprenorphine education and training program for primary care residents: implementation and evaluation. Subst Abus. 2013;34(3):242-247.
38. McCarty D, Rieckmann T, Green C, Gallon S, Knudsen J. Training rural practitioners to use buprenorphine: using The Change Book to facilitate technology transfer. J Subst Abuse Treat. 2004;26:203-208.
39. Daniels AM, Salisbury-Afshar E, Hoffberg A, Agus D, Fingerhood MI. A novel community-based buprenorphine program: client description and initial outcomes. J Addict Med. 2014;8(1):40-46.
40. Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015;48(1):104-111.
41. Results From the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
42. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2003-2012 (ICPSR 34933-v1). Ann Arbor, MI: Inter-University Consortium for Political and Social Research; 2013.
43. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2009-2012. Restricted Use Data Files. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
44. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National Survey of Substance Abuse Treatment Services (N-SSATS), 2003-2012 (ICPSR 34968). Ann Arbor, MI: Inter-University Consortium for Political and Social Research; 2014.
45. Substance Abuse and Mental Health Services Administration. Buprenorphine Physician and Treatment Program Locator. Available at: http://buprenorphine.samhsa.gov/bwns-locator/index.html. Accessed November 18, 2014.
46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
47. US Census Bureau, Population Division. Population estimates. Available at: http://www.census.gov/popest/index.html. Accessed November 18, 2014.
48. Arfken CL, Johanson CE, Menza SD, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39(2):96-104.
49. Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3:17.
50. Heinrich CJ, Cumming GR. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment. Health Serv Res. 2014;49(1):127-152.
51. Vermont Agency of Human Services. Integrated treatment for substance use dependence: "Hub/Spoke"Initiative - phase 1: opiate dependence. Available at: http://www.healthvermont.gov/adap/documents/HUBSPOKEBriefingDocV122112.pdf. Accessed December 11, 2014.
52. Centers for Medicare and Medicaid Services. Informational bulletin: medication assisted treatment for substance use disorder. Available at: http://www.medicaid.gov/Federal-Policy-Guidance/Downloads/CIB-07-11-2014.pdf. Accessed December 11, 2014.
53. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 42 U.S.C. §§ 18001-18121 (2010).
54. White WL. Medication-assisted recovery from opioid addiction: historical and contemporary perspectives. J Addict Dis. 2012;31(3):199-206.
55. Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936-941.
56. Scott JD, Unruh KT, Catlin MC, et al. Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States. J Telemed Telecare. 2012;18(8):481-484.
57. Hall G, Neighbors CJ, Iheoma J, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J Subst Abuse Treat. 2014;46(4):511-515.
58. King VL, Brooner RK, Peirce JM, Kolodner K, Kidorf MS. A randomized trial of Web-based videoconferencing for substance abuse counseling. J Subst Abuse Treat. 2014;46(1):36-42.
59. 2011 Opioid Treatment Program Survey: Data on Substance Abuse Treatment Facilities With OTPs. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. BHSIS Series S-65, HHS Publication No. (SMA) 14-4807.
60. Aletraris L, Bond Edmond M, Roman PM. Adoption of injectable naltrexone in US substance use disorder treatment programs. J Stud Alcohol Drugs. 2015;76(1):143-151.
61. McDonald DC, Carlson KE. The ecology of prescription opioid abuse in the USA: geographic variation in patients' use of multiple prescribers ("doctor shopping"). Pharmacoepidemiol Drug Saf. 2014;23(12):1258-1267.
62. Dasgupta N, Kramer ED, Zalman MA, et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend. 2006;82(2):135-142.